Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Novel transcript, sense overlapping TAF15", ENSG00000270894, is annotated as a non-coding RNA gene with overlap to TAF15; it does not encode a well-characterized therapeutic target or receptor. The canonical protein encoded by TAF15 (TATA-binding protein-associated factor 15) is a member of the FET family of atypical RNA-binding proteins, participating in gene regulation at both the transcriptional and post-transcriptional levels. TAF15 has roles in RNA splicing, mRNA maturation, and is subject to regulation by phosphorylation (e.g., via cAMP-PKA signaling), impacting its RNA-binding pattern[3]. TAF15 is implicated in neural development, particularly dorsoanterior structures, and has disease associations including ALS and several cancers[3][4]. However, "novel transcript, sense overlapping TAF15" (ENSG00000270894) itself is not a canonical receptor, enzyme, or druggable therapeutic target as currently defined, but rather an uncharacterized RNA, and thus is likely a non-coding transcript or annotation artifact[1]. \n\n**Note:** \n- The main entry here is not a protein-coding therapeutic target but a transcript annotation overlapping the TAF15 locus. \n- TAF15 is a well-characterized protein with important biological roles, but the queried entity ("novel transcript, sense overlapping TAF15", ENSG00000270894) is not itself considered a standard drug target, and may be a non-functional RNA or a transcript with unclarified biological relevance[1]. \n- If you are seeking information on the TAF15 protein itself, refer to "TATA-binding protein-associated factor 15 (TAF15)" as the canonical entity. \n- No drugs are known to target ENSG00000270894 or TAF15 directly.\n\nSources: [1][3][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TATA-binding protein-associated factor 15 (TAF15).